solvent or diluent such as an alcohol (e.g., methanol or  ethanol) or an ether ( e.g., IBF). The pH of aqueous mixtures  is typically in a range of from about 1 to about 7. The  temperature of the mixture is suitably maintained in a range  of from about 15 to about 30°  C. (e.g., about 25°  C.). In a  typical procedure, Compound I is mixed with an aqueous or  organic suspension of the cation exchange resin. The adsorp› tion of drug onto the resin can be detected by measuring a  change in the pH of an aqueous medium, or by measuring a  change in concentration of the counterion (sodium) or of  Compound I. The resulting Compound I-resin complex is  collected and washed (e.g., with alcohol and/or water) to  insure removal of any unbound drug. The resin complex can  then be air- or vacuum- dried at room or elevated tempera› ture. Further description of techniques for adsorption of a  drug onto the cation exchange resin particles can be found  in the art, for example, in U.S. Pat. No. 2,990,332 and U.S.  Pat. No. 4,221,778, both of which are herein incorporated by  reference in their entireties.  [0301]  Binding of drug to resin can be accomplished  according to four general reactions: (a) resin (Na-form) plus  drug (salt form); (b) resin (Na-form) plus drug (as free base);  (c) resin (H-form) plus drug (salt form); and (d) resin  (H-form) plus drug (as free base). All of these reactions  except (d) have cationic by-products, which compete with  the cationic form of Compound I for binding sites on the  resin and thus can reduce the amount of drug bound at  equilibrium. Stoichiometric binding of drug to resin can be  accomplished through reaction (d). The binding may be  performed, for example, as a batch or column process, as is  known in the art.  [0302]  The complex typically has a weight ratio of Com› pound I to resin in the range of from about 1: 10 to about 10: 1  (e.g., from about 1:5 to about 5:1 or from about 1:3 to about  3:1) and more typically from about 1:2 to about 2:1 (e.g.,  about 1:1).  [0303]  The amount of the Compound I complexed with  the ion exchange resin is suitably in the range from about 15  to about 80% by weight of the Compound I-resin complex,  and is typically in the range of from about 20 to about 70%  by weight of the Compound I-resin complex. In one aspect  of the invention, the amount of Compound I complexed to  the ion exchange resin is in the range from about 25 to about  50% by weight of the Compound I-resin complex.  [0304]  The Compound I-cation exchange resin complex is  suitably administered orally. The complex will enter the  acidic environment of the stomach (pH of about 2 to 3),  wherein the ionized form of Compound I (e.g., ammonium)  can be ion exchanged with other cations found in the  stomach (e.g.,  H+).  Due to a concentration gradient, the  exchanged Compound I cation is released from the poly› meric support and will diffuse out of the resin. Compound I  can then be absorbed and enter the circulation.  [0305]  Suitable forms for oral administration include liq› uid forms such as a suspension and solid forms such as a  tablet or capsule. A tablet can be obtained by directly  compressing the resin complex of the invention, which can  be in the form of granules, with one or more excipients such  as diluents, binders, lubricants, glidants, disintegrants, col› oring agents and flavoring agents. Excipients suitable for use  in preparing the present invention in tablet form include  th~hse described in  Remington’s Pharmaceutical Sciences,  18 edition, 1990, pp. 1635-1638, which is herein incorpo› rated by reference in its entirety. A granule is a solid  preparation comprising small particles containing the Com› pound I-resin complex of the invention and one or more  excipients such as lactose, mannitol, microcrystalline cellu› lose or talc. The granules can be prepared by wet or dry  granulation techniques known in the art.  A  capsule is a  container, such as a gelatin shell, for the resin complex of the  invention, and can be a dry-filled, wet-filled, liquid-filled or  granule-filled shell. A solid form can be of different shapes,  sizes or colors depending, for example, on the type and  amount of Compound I-resin complex and the excipients (if  any) it contains.  [0306]  Compound I can be administered orally to humans  in a dosage range of 0.001 to 1000 mg/kg body weight in  divided doses. One preferred dosage range is 0.1 to 200  mg/kg body weight orally in divided doses. Another pre› ferred dosage range is 0.5 to 100 mg/kg body weight orally  in divided doses. For oral administration, the compositions  of the present invention are preferably provided in the form  of capsules or tablets containing 1 to 1000 milligrams of the  active ingredient, particularly 1, 5, 10, 15. 20, 25, 50, 75,  100,150,200,250,300,400,500,600,750,800,900, and  1000 milligrams of the active ingredient for the symptomatic  adjustment of the dosage to the patient to be treated.  It will  be understood, however, that the specific dose level and  frequency of dosage for any particular patient may be varied  and will depend upon a variety of factors including the  activity of the specific compound employed, the metabolic  stability and length of action of that compound, the age,  body weight, general health, sex, diet, mode and time of  administration, rate of excretion, drug combination, the  severity of the particular condition, and the host undergoing  therapy.  [0307]  Oral administration to human subjects suitably  follows a meal or a soda, which typically will increase  stomach acidity and thus promote release of the drug from  the resin.  [0308]  In a preferred embodiment, the oral dosage form is  a capsule containing from about 10 to about 1000 mg of  Compound I complexed with a cation exchange resin. In one  aspect of this embodiment, the cation exchange resin is  Amberlite IRP-69, wherein the amount of Compound I  complexed with the resin is in the range from about 15 to  about 75% by weight of the Compound I-resin complex.  [0309]  The present invention also includes combinations  of the composition of the invention comprising the Com› pound I-cation exchange resin complex with one or more  agents useful in the treatment of  HIV  infection and/or  AIDS.  For example, the compounds of this invention may be  effectively administered in combination with effective  amounts of the  HIV/AIDS  antivirals, imunomodulators,  antiinfectives, or vaccines, such as those in Table 1 as  follows:  US 2004/0067216 Al  17  Apr. 8, 2004 